Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
anti-TRAIL-R2 (human), mAb (TR2.21)
460
CHF
CHF 460.00
In stock
AG-20B-0028-C100100 µgCHF 460.00
Figure 1: Immunohistochemistry detection of endogenous TRAIL-R2 in paraffin-embedded human carcinoma tissues (colon, tonsil) using mAb to TRAIL-R2 (TR2.21) (Prod. No. AG-20B-0028).
Figure 2: Negative control.
| Product Details | |
|---|---|
| Synonyms | TRAIL Receptor 2; DR5; KILLER; TNFRSF 10B; CD262 |
| Product Type | Monoclonal Antibody |
| Properties | |
| Clone | TR2.21 |
| Isotype | Mouse IgG1 |
| Source/Host | Purified from concentrated hybridoma tissue culture supernatant. |
| Immunogen/Antigen | Recombinant human TRAIL-R2 (DR5). |
| Application |
Flow Cytometry |
| Crossreactivity | Human |
| Specificity |
Recognizes human TRAIL-R2. Does not cross-react with human TRAIL-R1, -R3 or -R4. |
| Purity | ≥95% (SDS-PAGE) |
| Purity Detail | Protein G-affinity purified. |
| Concentration | 1mg/ml |
| Formulation | Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. |
| Isotype Negative Control | |
| Other Product Data |
Specially developed for the immunohistochemical detection of TRAIL-R2 in paraffin embedded tissue. Has been shown to detect TRAIL-R2 expressed at endogenous levels in paraffin-embedded tissue in different mammary carcinoma tissues. For IHC (paraffin sections) TRAIL-R2 specific staining protocol (see PDF on web). |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| Protocols |
 Download PDF |
| MSDS |
Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
TRAIL-R2 is a receptor for the cytotoxic ligand TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-κB.
Product References
- TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window: R. Koschny, et al.; Hepatol. 45, 649 (2007)
- Troglitazone-mediated sensitization to TRAILinduced apoptosis is regulated by proteasomedependent degradation of FLIP and ERK1/2- dependent phosphorylation of BAD: K. Grund, et al.; Cancer Biol. Ther. 7, 1982 (2008)
- Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer: T. M. Ganten, et al.; J. Mol. Med. 87, 995 (2009)
- Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer: S. Macher-Goeppinger, et al.; Clin. Cancer Res. 15, 650 (2009)
- Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma: R. Koschny, et al.; BMC Cancer 13, 532 (2013)
- Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis: S. von Karstedt, et al.; Cancer Cell 27, 561 (2015)
- IAPs cause resistance to TRAIL-dependent apoptosis in follicular 1 thyroid cancer: T.A. Werner, et al.; Endocr. Relat. Cancer 17, 0479 (2018)
Related Products
